A password is required to submit a request for an internal transfer. In order to obtain the password you can check any of the following resources: Login to the employee portal, check the current issue of "Regional High Points" newsletter, contact HR, or read this week's "Daily Announcements".
is a virus that is spread by mosquitoes. It can cause swelling of the brain. It also affects the central nervous system. Japanese encephalitis can cause severe complications, like long-term neurological disability and death.
People get Japanese encephalitis when they are bitten by a mosquito infected with the virus. Japanese encephalitis is a common cause of viral encephalitis in Asia. It can be prevented by vaccines.
Many people with the infection may have no symptoms. If symptoms develop, they can include:
The vaccine is recommended for people who are traveling to Asia and are:
Planning to stay at least a month where there have been Japanese encephalitis
Planning on staying less than a month, but will be in rural areas or outdoors a lot
Going to an area of Japanese encephalitis outbreaks
Unsure where they will be staying
Lab workers who may be exposed to Japanese encephalitis should also get the vaccine.
There is no vaccine available in the United States for young children. Children under age 17 who will be traveling to a high-risk area can visit a travel clinic abroad or enroll in a clinical trial. Visit the http://www.cdc.gov... (CDC) website for more information.
The Japanese encephalitis vaccine is given in a series of 2 shots within 28 days. The last dose needs to be given within 1 week of traveling to Asia.
What Are the Risks Associated With the Japanese Encephalitis Vaccine? TOP
Like any vaccine, the Japanese encephalitis vaccine can cause problems, such as severe allergic reactions. The risk of serious harm or death is extremely small.
The most commonly reported problems from the Japanese encephalitis vaccine are mild and include:
Soreness, redness, or swelling near the injection site
Clinical trials sites in the United States for Ixiaro in children under 17. Centers for Disease Control and Prevention website. Available at ...(Click grey area to select URL) Accessed November 19, 2013.
Dubischar-Kastner K, Kaltenboeck A, et al. Safety
analysis of a Vero cell culture-derived Japanese encephalitis vaccine, IXIARO
(IC51), in 6 months of follow-up.
Fischer M, Lindsey N, et al; Centers for Disease Control and
Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory
Committee on Immunization Practices (ACIP).
MMWR Recomm Rep.
Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain.
Expert Rev Vaccines. 2011;10(3):355-364.
Halstead SB, Thomas SJ. Japanese encephalitis: new options for active
Clin Infect Dis.
Japanese encephalitis. EBSCO DynaMed website. Available at: ...(Click grey area to select URL) Updated May 22, 2013. Accessed November 19, 2013.
Lehtinen VA, Huhtamo E, et al. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand.
J Clin Virol. 2008;43(1):93-95.
Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and
Curr Opin Infect Dis.
Last reviewed November 2014 by David Horn, MD Last Updated: 11/19/2013
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.